Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients

Oral and Maxillofacial Surgery

Volumn 16, Issue 2, 2012, Pages 189-196

  Eckert, A W ^a   Kappler, M ^a   Schubert, J ^a   Taubert, H ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

HIF; Hypoxia; Oral squamous cell carcinoma; Pathways

Indexed keywords

ARNT PROTEIN, HUMAN; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; GLUCOSE TRANSPORTER 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; TUMOR ANTIGEN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CELL HYPOXIA; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MORTALITY; MOUTH MUCOSA; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; STATISTICS; SURVIVAL RATE;

ANTIGENS, NEOPLASM; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOUTH MUCOSA; MOUTH NEOPLASMS; PROGNOSIS; STATISTICS AS TOPIC; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861668879     PISSN: 18651550     EISSN: 18651569     Source Type: Journal    
DOI: 10.1007/s10006-012-0335-8     Document Type: Review

References (84)

1. Abreu L, Kruger E, Tennant M (2010) Oral cancer in Western Australia: 1982-2006: a retrospective epidemiological study. Oral Pathol Med 39: 376-381.
2. Zini A, Czerninski R, Sgan-Cohen HD (2010) Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. Oral Pathol Med 39: 299-305.
3. Oliveira LR, Ribeiro-Silva A (2011) Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 40: 298-307.
4. Schliephake H (2003) Prognostic relevance of molecular markers of oral cancer-a review. Int J Oral Maxillofac Surg 32: 233-245.
5. Lothaire P, Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G, Awada A (2006) Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28: 256-269.
6. Kim KY, Li S, Cha JD, Zhang X, Cha IH (2011) Significance of molecular markers in survival prediction of oral squamous call carcinoma. Head Neck. doi: 10. 1002/hed. 21856.
7. Pérez-Sayáns M, Suárez-Peñaranda JM, Pilar GD, Barros-Angueira F, Gándara-Rey JM, García-García A (2011) Hypoxia-inducible factors in OSCC. Cancer Lett 313: 1-8.
8. Cassavaugh J, Luonsbury KM (2011) Hypoxia-mediated biological control. J Cell Biochem 112: 735-744.
9. Semenza GL (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60: 591-597.
10. Semenza GL (2009) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 1-6.
11. Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
12. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastas Rev 26: 225-239.
13. Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237.
14. Denko NC (2008) Hypoxia, HIF-1 and glucose metabolism in the solid tumor. Nature Rev Cancer 8: 705-713.
15. Swietach P, Vaughan-Jones RD, Harris AL (2007) Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastas Rev 26: 299-310.
16. Rankin EB, Giaccia AJ (2008) The role of hypoxia inducible factors in tumorigenesis. Cell Death Differ 15: 678-685.
17. Calzada MJ, del Peso L (2007) Hypoxia-inducible factors in cancer. Clin Transl Oncol 5: 278-289.
18. Sendoel A, Kohler I, Fellmann C, Lowe SW, Hengartner MO (2010) HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 465: 577-583.
19. Keith B, Johnson RS, Simon MC (2011) HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22.
20. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514.
21. Huang LE, Bunn HF (2003) Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 278: 19575-19578.
22. Harris AL (2002) Hypoxia-a key regulatory factor in tumor growth. Nature Rev Cancer 2: 38-47.
23. Semenza GL (2003) Targting HIF-1 for cancer therapy. Nat Rev Cancer 3(10): 721-731.
24. Eckert AW, Schütze A, Lautner MHW, Taubert H, Schubert J, Bilkenroth U (2010) HIF-1alpha is a prognostic marker in oral squamous cell carcinomas. Int J Biomark 25: 87-92.
25. Eckert AW, Schubert J, Taubert H (2010) Optimising the therapeutic ration in head and neck cancer. Lancet Oncol 11: 511-512.
26. Roh JI, Cho K-J, Kwon GY, Ryu CH, Chang HW, Choi SH, Nam SY, Kim SY (2009) The prognostic value of hypoxia markers in t2-staged oral tongue cancer. Oral Oncol 45: 63-68.
27. Uehara M, Sano K, Ikeda H, Nonaka M, Asahina I (2009) Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncol 45: 241-246.
28. Winter SC, Shah KA, Han C et al (2006) The relation between hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107: 757-766.
29. Beasley NJP, Leek R, Alam M et al (2002) Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62: 2493-2497.
30. Koukourakis MI, Bentzen SM, Giatromanolaki A et al (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24: 727-735.
31. Lin P-Y, Yu C-H, Wang J-T et al (2008) Expression of hypoxia-inducible factor 1α is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 37: 18-25.
32. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Burger H (2005) HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5: 84.
33. Aebershold DM, Burri P, Beer KT et al (2001) Expression of hypoxia-inducible factor 1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916.
34. Warburg O (1956) On respiratory impairment in cancer cells. Science 124: 269-270.
35. Chiche J, Brahimi-Horn C, Pouysségur J (2010) Tumor hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 14: 771-794.
36. Reißer C, Eichhorn K, Mende CH (1999) Glukoseaufnahme maligner Kopf-Hals-Tumoren. HNO 47: 712-717.
37. Reißer C, Eichhorn K, Herold-Mende C, Born A, Bannasch P (1999) Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 80: 194-198.
38. Brahimi-Horn C, Pouysségur J (2006) The role of hypoxia-inducible factor in tumor growth and invasion. Bull Cancer 93: 73-80.
39. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, Bartenstein P, Wagner W, Whiteside TL (2003) Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97: 1015-1024.
40. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K (2004) Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 1: 5-12.
41. Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, da Cunha IW, Lourenço SV, Soares FA (2010) GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 15: 2374-2387.
42. Eckert AW, Lautner MH, Taubert H, Schubert J, Bilkenroth U (2008) Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep 20: 1381-1385.
43. Mayer A, Höckel M, Horn LC, Schmidberger H, Vaupel P (2011) GLUT-1 staining of squamous cell carcinomas of the uterine cervix identifies a novel element of invasion. Int J Oncol 38: 145-150.
44. Potente M, Gerhardt H, Carmeliet (2011) Basic and therapeutic aspects of angiogenesis. Cell 146: 873-887.
45. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
46. Nayak S, Goel MM, Chandra S, Bhatia V, Mehrotra D, Kumar S, Makker A, Rath SK, Agarwal SP (2012) VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas. Oral Oncol 48: 233-239.
47. Fox S (1997) Tumour angiogenesis and prognosis. Histopathology 30: 294-301.
48. Shemiranio B, Crowe DL (2002) Hypoxic induction of HIF-1α and VEGF expression in head and neck squamous cell carcinoma cell lines is mediated by stress activated protein kinases. Oral Oncol 38: 251-257.
49. Mohamed KM, Le A, Duong H, Wu Y, Zhang Q, Messadi DV (2004) Correlation between VEGF and HIF-1alpha expression in human squamous cell carcinoma. Exp Mol Pathol 76: 143-152.
50. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R (2004) Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J Pathol 202: 367-374.
51. Artese L, Rubini C, Ferrero G, Fioroni M, Santinelli A, Piattelli A (2001) Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res 21: 689-695.
52. Chien SY, Su CY, Hwang CF, Chuang HC, Chen CM, Huang CC (2006) High expressions of CD 105 and VEGF in early oral cancer predict potential cervical metastasis. J Surg Oncol 94: 413-417.
53. Shao Z, Zhang WF, Chen XM, Shang ZJ (2008) Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol 44: 1110-1117.
54. Maeda T, Matsumura S, Hiranuma H, Jikko A, Furukawa S, Ishada T, Fuchihata H (1998) Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumor progression and p53 gene status. J Clin Pathol 51: 771-775.
55. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG (2000) Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal sqamous cell carcinoma. J Clin Oncol 18: 2046-2052.
56. Smith BD, Smith GL, Carter D, Di Giovanna MP, Kasowitz KM, Sasaki CT, Haffty BG (2001) Moleular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127: 780-785.
57. Kyzas PA, Cunha IW, Ioannidis JP (2005) Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 11: 1434-1440.
58. Mǎrgǎritescu C, Pirici D, Stîngǎ A, Simionescu C, Raica M, Mogoantǎ L, Stepan A, Ribatti D (2010) VEGF expression and angiogenesis in oral squamous cell carcinoma: an immunohistochemical and morphometric study. Clin Exp Med 10: 209-214.
59. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z (2008) Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 28: 1659-1666.
60. Shang ZJ, Li JR, Li ZB (2007) Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma. J Oral Maxillofac Surg 65: 17-21.
61. Shang ZJ, Li ZB, Li JR (2006) VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int J Oral Maxillofac Surg 35: 533-538.
62. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H (2004) Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol 40: 13-20.
63. de Cicco RL, Watson JC, Bassi DE, Litwin S, Klein-Szanto AJ (2004) Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression. Clin Cancer Res 10: 4480-4488.
64. Muñoz-Guerra MF, Marazuela EG, Martin-Villar E, Quintanilla M, Gamallo C (2004) Prognostic significance of intratumoral lymphangiogenesis in squamous cell carcinoma of the oval cavity. Cancer 100(3): 553-560.
65. Bolte K, Kappler M, Bilkenroth U, Taubert H, Schubert J, Eckert AW (2012) Expression of VEGF-C and other proteins as prognostic markers in OSCC (in preparation).
66. Sedivy R, Beck-Mannagetta J, Haverkampf C, Battistutti W, Hönigschnabl S (2003) Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell carcinoma. J OralPathol Med 32: 455-460.
67. Naruse T, Kawasaki G, Yanamoto S, Mizuno A, Umeda M (2011) Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: correlation with mTOR-HIF-1α pathway. Anticancer Res 31: 4429-4437.
68. Nógrádi A (1998) The role of carbonic anhydrases in tumors. Am J Pathol 153: 1-4.
69. Konno H, Ishii G, Nagai K, Yoshida J, Nishimura M, Nara M, Fujii T, Murata Y, Miyamoto H, Ochiai A (2006) Carbonic anhydrase IX expression is associated with tumor progression and poor prognosis of lung adenocarcinoma. Lung Cancer 54: 409-418.
70. Hoogsteen IJ, Marres HAM, Wijffels KIEM, Rijken PFJW, Peters JPW, van der Hoogen FJA, Oosterwijk E, van der Kogel A, Kaanders JHAM (2005) Colonization of carbonic anhydrase and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 11: 97-106.
71. Kondo Y, Yoshikawa K, Omura Y, Shinohara A, Kazaoka Y, Sano J, Mizuno Y, Yokoi T, Yamada S (2011) Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma. Oncol Rep 25: 1227-123.
72. Choi SW, Kim JY, Park JY, Cha IH, Kim J, Lee S (2008) Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol 39: 1317-1322.
73. Brockton NT, Klimowicz AC, Bose P, Petrillo SK, Konno M, Rudmik L, Dean M, Nakoneshny SC, Matthews TW, Chandarana S, Lau HY, Magliocco AM, Dort JC (2012) High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. Oral Oncol. doi: 10. 1016/j. ovaloncology. 2012. 01. 018.
74. Eckert AW, Lautner MHW, Taubert H, Schütze A, Bolte K, Bache M, Kappler M, Schubert J, Bilkenroth U (2009) Co-expression of HIF-1α and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med 39: 313-317.
75. Zeng W, Wan R, Zheng Y, Singh SR, Wei Y (2011) Hypoxia, stem cells and bone tumor. Cancer Lett 313: 129-136.
76. Gatenby RA, Gillies RJ (2004) Why do cancer have high anaerobic glycolysis? Nature Rev Cancer 4: 891-899.
77. Le Q-T, Kong C, Lavori P, O'Byrne K, Erler JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N, Giaccia AJ, Kong AC (2007) Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69: 167-175.
78. Eckert AW, Lautner HMW, Schütze A, Taubert H, Schubert J, Bilkenroth U (2011) Co-expression of hypoxia-inducible factor 1 alpha (HIF1α) and glucose transporter 1 (GLUT-1) is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology 58: 1138-1147.
79. Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY (2011) Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. doi: 10. 1002/hed. 21945.
80. Kaluz S, Kaluzova M, Chrastina A, Olive PL, Pastoreková S, Pastorek J, Lerman MI, Stanbridge E (2002) Lowered oxygen tension induces expresseion of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1α stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 62: 4469-4477.
81. Jokilehto T, Jaakkola PM (2010) The role of prolylhydroxylases in tumour growth. J Cell Mol Med 14(4): 758-770.
82. Mayer A, Höckel M, Vaupel P (2008) Endogenous hypoxia markers: case not proven! Adv Exp Med Biol 614: 127-136.
83. Corry J, Peters LJ, Rischin D (2010) Optimising the therapeutic ration in head and neck cancer. Lancet Oncol 11: 287-291.
84. Nayak S, Goel MM, Chandra S, Bhatia V, Mehrotra D, Kumar S, Makker A, Rath SK, Agarwal SP (2012) VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas. Oral Oncol 48: 233-239.